Table 2 Correlation of p16/p53/MDM2 immunoprofile in ESCC patients with p16 methylation and clinicopathological features
| Â | Alteration | ||||
|---|---|---|---|---|---|
| Â | a | b | c | d | p value |
p16 methylation | Â | Â | Â | Â | Â |
   Positive | 3 (33.3) | 6 (46.2) | 12 (70.6) | 10 (90.9) | 0.028 |
   Negative | 6 (66.7) | 7 (53.8) | 5 (29.4) | 1 (9.1) |  |
Tobacco use | Â | Â | Â | Â | Â |
   Positive | 2 (22.2) | 7 (58.3) | 3 (21.4) | 2 (18.2) | 0.145 |
   Negative | 7 (77.8) | 5 (41.7) | 11 (78.6) | 9 (81.8) |  |
Histology | Â | Â | Â | Â | Â |
   Well | 3 (33.3) | 7(53.8) | 6 (50) | 9 (81.8) | 0.173 |
   Moderate | 2 (22.2) | 4 (30.8) | 5 (41.7) | 2 (18.2) |  |
   Poor | 4 (44.4) | 2 (15.4) | 1 (8.3) | 0 (0.0) |  |
Tissue | Â | Â | Â | Â | Â |
   Tumor | 9 (56.2) | 13 (43.4) | 17 (80.9) | 11 (100) | 0.001 |
   Normal | 7 (43.8) | 17 (56.6) | 4 (19.1) | 0 (0.0) |  |